Get Live Data

Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Latest Share Chat

  2. Share Prices
  3. Immupharma Share Price
  4. Immupharma Share Regulatory News
  5. Holding(s) in Company

Pin to quick picksImmupharma Regulatory News (IMM)

Immupharma Information

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.25
Bid: 2.10
Ask: 2.25
Change: 0.035 (1.64%)
Spread: 0.15 (7.143%)
Open: 2.17
High: 2.27
Low: 2.17
Prev. Close: 2.14
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

22 Mar 2017 08:51

RNS Number : 1863A
Immupharma PLC
22 March 2017
 

22 MARCH 2017

 

 

 

 

NOTIFICATION OF MAJOR INTEREST BY ALTO INVEST

 

 

ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that it has received notification by Alto Invest ("Alto") confirming its holding in ImmuPharma of 5,802,317 million Ordinary Shares in the capital of the Company, representing 4.38% of ImmuPharma's total voting rights figure of  132,522,985 Ordinary Shares.

 

Commenting, Tim McCarthy, Chairman of ImmuPharma, said: "We are delighted to be able to disclose Alto's increased holding in ImmuPharma as a further key major institutional investor which participated in our recent successful £4.1 million fundraising demonstrating its continued support for ImmuPharma."

 

Ends

 

For further information please contact:

 

ImmuPharma plc (www.immupharma.org)

+ 44 (0) 20 7152 4080

Tim McCarthy, Chairman

Lisa Baderoon, Head of Investor Relations

Twitter: @immupharma

 

+ 44 (0) 7721 413496

 

 

Northland Capital Partners Limited (NOMAD & Broker)

Patrick Claridge, David Hignell, Michael Mackintosh, Corporate Finance

Rob Rees, Corporate Broking

+44 (0)20 3861 6625

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLVLLBLDXFZBBK
12345678910
Date   Source Headline
8th Jul 20138:00 amRNSIMMUPHARMA APPOINTS WORLDWIDE KEY OPINION LEADERS
5th Jun 20137:00 amRNSHolding(s) in Company
23rd May 201312:29 pmRNSResult of AGM
21st May 20137:00 amRNS£50M Financing Facility - Darwin Strategic
22nd Apr 20137:00 amRNSPosting of Annual Report and AGM Notice
9th Apr 20137:00 amRNSPreliminary Results
28th Feb 20137:01 amRNSImmuPharma Commences Trading on Stuttgart Exchange
28th Jan 20134:03 pmRNSDirector/PDMR Shareholding - Replacement
28th Jan 20131:18 pmRNSDirector/PDMR Shareholding
28th Jan 20139:33 amRNSCNRS Confirms Lupuzor's (TM) Effectiveness
15th Nov 20127:30 amRNSLupuzor Presentation
5th Nov 20127:00 amRNSLupuzor Presentation
3rd Oct 20127:00 amRNSNotification of Major Interest in Shares
26th Sep 20127:01 amRNSFirst Cancer Patients in New Trial Begin Dosing
26th Sep 20127:00 amRNSInterim Results
20th Sep 20127:00 amRNSNotification of Interim Results
7th Sep 201211:12 amRNSRodman and Renshaw Conference
17th Aug 20129:11 amRNSNotification of Major Interest in Shares
11th Jul 20127:00 amRNSVoted Best Medical Research & Development Company
9th Jul 20127:00 amRNSNew Corporate Website
3rd Jul 20127:00 amRNSAppointment of Joint Broker
23rd May 201212:20 pmRNSAnnual General Meeting: 2012
17th Apr 20127:00 amRNSPosting of Annual Report and AGM Notice
27th Mar 20127:00 amRNSPreliminary Results
29th Feb 20127:00 amRNSAppoints Head of Investor Relations
24th Jan 201212:44 pmRNSDirector's Dealings
3rd Nov 20117:00 amRNSLupuzorT granted approval to start phase III
1st Nov 201110:23 amRNSNotification of Major Interest in Shares
1st Nov 201110:18 amRNSNotification of Major Interest in Shares
21st Oct 20117:00 amRNSImmuPharma regains Lupuzor rights
30th Sep 20117:00 amRNSINTERIM RESULTS ANNOUNCEMENT
23rd Sep 20119:34 amRNSNotification of Interim Results
12th Jul 20112:47 pmRNSNotification of Major Interest in Shares
19th May 201111:19 amRNSResult of Annual General Meeting
5th May 20117:00 amRNSIPP-204106 paper published
26th Apr 20114:38 pmRNSAnnual Report and Accounts & Notice of AGM
5th Apr 20117:00 amRNSPreliminary Results
30th Mar 20117:00 amRNSNotification of Preliminary Results
21st Feb 20117:00 amRNSUpdate on progress of Phase I/IIa Clinical Trial
19th Oct 20101:08 pmRNSUpdate on Phase IIa Clinical Trial
11th Oct 20102:30 pmRNSNotification of major interests in shares
11th Oct 20102:30 pmRNSAdditional Listing and Total Voting Rights
30th Sep 20107:00 amRNSInterim Results
28th Sep 201010:18 amRNSNotification of Interim Results
28th Jun 20107:00 amRNSPresentation at the International Congress
23rd Jun 20107:40 amRNSReplacement of Development release
23rd Jun 20107:00 amRNSCephalon initiates critical steps in development
17th Jun 201012:02 pmRNSResult of AGM
10th Jun 201010:55 amRNSAnnual Report and Accounts
19th May 20107:01 amRNSInitiation Of Phase I/IIA Studies In Cancer
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.